INCY vs INSM
Incyte and Insmed Incorporated, both Healthcare
Insmed Incorporated is the larger company at $23B against $20B. Over the past year INCY returned +31% against -30% for INSM. The RyuScore puts INCY ahead, 82 against 18 out of 100.
| Figure | INCY | INSM |
|---|---|---|
| Last close | $113 | $101 |
| Market cap | $20B | $23B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 15.9 | n/a |
| 1-year return | +31% | -30% |
| 5-year return | +56% | +269% |
| RyuScoresector-relative, 1–10 | 82/100 | 18/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.